

Irene C Huffnagel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4195851/publications.pdf>

Version: 2024-02-01

18
papers

572
citations

840776

11
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

701
citing authors

#	ARTICLE	IF	CITATIONS
1	Magnetic resonance spectroscopy as marker for neurodegeneration in X-linked adrenoleukodystrophy. <i>NeuroImage: Clinical</i> , 2021, 32, 102793.	2.7	1
2	Optical coherence tomography to measure the progression of myelopathy in adrenoleukodystrophy. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1064-1072.	3.7	2
3	Imaging in X-Linked Adrenoleukodystrophy. <i>Neuropediatrics</i> , 2021, 52, 252-260.	0.6	8
4	Five men with arresting and relapsing cerebral adrenoleukodystrophy. <i>Journal of Neurology</i> , 2021, 268, 936-940.	3.6	2
5	Molecular Biomarkers for Adrenoleukodystrophy: An Unmet Need. <i>Cells</i> , 2021, 10, 3427.	4.1	14
6	Optical coherence tomography shows neuroretinal thinning in myelopathy of adrenoleukodystrophy. <i>Journal of Neurology</i> , 2020, 267, 679-687.	3.6	6
7	Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2127-2136.	3.7	19
8	Postural Body Sway as Surrogate Outcome for Myelopathy in Adrenoleukodystrophy. <i>Frontiers in Physiology</i> , 2020, 11, 786.	2.8	3
9	Spinal cord atrophy as a measure of severity of myelopathy in adrenoleukodystrophy. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 852-860.	3.6	13
10	Overall intact cognitive function in male X-linked adrenoleukodystrophy adults with normal MRI. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 217.	2.7	5
11	Disease progression in women with X-linked adrenoleukodystrophy is slow. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 30.	2.7	58
12	Longitudinal diffusion MRI as surrogate outcome measure for myelopathy in adrenoleukodystrophy. <i>Neurology</i> , 2019, 93, e2133-e2143.	1.1	14
13	Progression of myelopathy in males with adrenoleukodystrophy: towards clinical trial readiness. <i>Brain</i> , 2019, 142, 334-343.	7.6	43
14	The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 118-126.	3.6	102
15	Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 209-215.	1.1	50
16	Mitochondrial Encephalopathy and Transient 3-Methylglutaconic Aciduria in ECHS1 Deficiency: Long-Term Follow-Up. <i>JIMD Reports</i> , 2017, 39, 83-87.	1.5	23
17	Adrenoleukodystrophy – neuroendocrine pathogenesis and redefinition of natural history. <i>Nature Reviews Endocrinology</i> , 2016, 12, 606-615.	9.6	189
18	Rhizomelic chondrodysplasia punctata and cardiac pathology. <i>Journal of Medical Genetics</i> , 2013, 50, 419-424.	3.2	20